Common Contracts

34 similar Co-Promotion Agreement contracts

Co promotion agreement for dapagliflozin
Co-Promotion Agreement • April 7th, 2023

AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.

AutoNDA by SimpleDocs

Standard Contracts

Co promotion agreement for dapagliflozin
Co-Promotion Agreement • May 3rd, 2021

AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.

Co promotion agreement for dapagliflozin
Co-Promotion Agreement • May 3rd, 2021

AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.

Co promotion agreement for dapagliflozin
Co-Promotion Agreement • May 3rd, 2021

AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.

Co promotion agreement for dapagliflozin
Co-Promotion Agreement • May 3rd, 2021

AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.

Co promotion agreement for dapagliflozin
Co-Promotion Agreement • May 3rd, 2021

AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.

Co promotion agreement for dapagliflozin
Co-Promotion Agreement • May 3rd, 2021

AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.

Co promotion agreement for dapagliflozin
Co-Promotion Agreement • May 3rd, 2021

AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.

Co promotion agreement for dapagliflozin
Co-Promotion Agreement • May 3rd, 2021

AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.

Co promotion agreement for dapagliflozin
Co-Promotion Agreement • May 3rd, 2021

AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.

Co promotion agreement for dapagliflozin
Co-Promotion Agreement • May 3rd, 2021

AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.

Co promotion agreement for dapagliflozin
Co-Promotion Agreement • May 3rd, 2021

AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.

Co promotion agreement for dapagliflozin
Co-Promotion Agreement • May 3rd, 2021

AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.

Co promotion agreement for dapagliflozin
Co-Promotion Agreement • May 3rd, 2021

AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.

Co promotion agreement for dapagliflozin
Co-Promotion Agreement • May 3rd, 2021

AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.

Co promotion agreement for dapagliflozin
Co-Promotion Agreement • May 3rd, 2021

AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.

Co promotion agreement for dapagliflozin
Co-Promotion Agreement • May 3rd, 2021

AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.

Co promotion agreement for dapagliflozin
Co-Promotion Agreement • May 3rd, 2021

AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.

Co promotion agreement for dapagliflozin
Co-Promotion Agreement • May 3rd, 2021

AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.

Co promotion agreement for dapagliflozin
Co-Promotion Agreement • May 3rd, 2021

AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.

Co promotion agreement for dapagliflozin
Co-Promotion Agreement • May 3rd, 2021

AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.

Co promotion agreement for dapagliflozin
Co-Promotion Agreement • May 3rd, 2021

AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.

AutoNDA by SimpleDocs
Co promotion agreement for dapagliflozin
Co-Promotion Agreement • May 3rd, 2021

AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.

Co promotion agreement for dapagliflozin
Co-Promotion Agreement • May 3rd, 2021

AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.

Co promotion agreement for dapagliflozin
Co-Promotion Agreement • May 3rd, 2021

AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.

Co promotion agreement for dapagliflozin
Co-Promotion Agreement • May 3rd, 2021

AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.

Co promotion agreement for dapagliflozin
Co-Promotion Agreement • May 3rd, 2021

AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.

Co promotion agreement for dapagliflozin
Co-Promotion Agreement • May 3rd, 2021

AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.

Co promotion agreement for dapagliflozin
Co-Promotion Agreement • May 3rd, 2021

AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.

Co promotion agreement for dapagliflozin
Co-Promotion Agreement • May 3rd, 2021

AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.

Co promotion agreement for dapagliflozin
Co-Promotion Agreement • May 3rd, 2021

AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.

Co promotion agreement for dapagliflozin
Co-Promotion Agreement • May 3rd, 2021

AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.

Co promotion agreement for dapagliflozin
Co-Promotion Agreement • May 3rd, 2021

AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.

Co promotion agreement for dapagliflozin
Co-Promotion Agreement • May 3rd, 2021

AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!